TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12642710

Group type: EXPERIMENTAL
Intervention: Premenopausal women with endemic fluorosis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with endemic fluorosis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Premenopausal controls
Number of subjects: 80
Study: 10428346

Group type: EXPERIMENTAL
Intervention: Prophylactic Augmentin
Number of subjects: 171

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 171
Study: 7567006

Group type: COMPARATOR
Intervention: 2% lidocaine in oxymetazoline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% tetracaine in oxymetazoline
Number of subjects: 0
Study: 2406858

Group type: EXPERIMENTAL
Intervention: Liquid bismuth subsalicylate (BSS) 60 mL four times daily (4.2 g of BSS/d) for 3 weeks
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: BSS 2 tablets four times daily (2.1 g of BSS/d) for 3 weeks
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: BSS 1 tablet four times daily (1.05 g of BSS/d) for 3 weeks
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo (two tablets taken four times daily) for 3 weeks
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: BSS (all dosages)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: BSS-treated subjects with diarrhea
Number of subjects: 234
Study: 7437276

Group type: EXPERIMENTAL
Intervention: Dipyrone 2.5 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 0
Study: 31536806

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE 0.625 mg/day) plus medroxyprogesterone acetate (MPA 2.5 mg/day)
Number of subjects: 27425

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE 0.625 mg/day) alone
Number of subjects: 27425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27425
Study: 30739657

Group type: EXPERIMENTAL
Intervention: ezetimibe + simvastatin
Number of subjects: 18144

Group type: COMPARATOR
Intervention: placebo + simvastatin
Number of subjects: 18144
Study: 28891251

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg q.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg q.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baricitinib (twice-daily regimen)
Number of subjects: 0
Study: 26702941

Group type: EXPERIMENTAL
Intervention: Airwall film dressing (group A)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard treatments (group B)
Number of subjects: 271
Study: 24806137

Group type: EXPERIMENTAL
Intervention: Nefopam (0.1 μg/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meperidine (0.1 μg/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nefopam and Meperidine (both at 0.1 μg/mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study: 22628593

Group type: EXPERIMENTAL
Intervention: High-flex PS TKR
Number of subjects: 24

Group type: COMPARATOR
Intervention: Gender-specific high-flexion PS TKR
Number of subjects: 24
Study: 19317814

Group type: EXPERIMENTAL
Intervention: 1500 mg of Ca(2+) orally, daily for 8 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 31
Study: 17804335

Group type: EXPERIMENTAL
Intervention: 10% ascorbate for 1 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10% ascorbate for 3 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10% ascorbate for 10 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20% ascorbate for 1 min
Number of subjects: 6

Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 6
Study: 15710809

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Atropine eye drops
Number of subjects: 419

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 419
Study: 11741362

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 3697

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3697
Study: 9836755

Group type: EXPERIMENTAL
Intervention: Rehabilitation focused on impairment (theoretically driven)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Rehabilitation oriented on disability (pragmatic)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 184
Study: 7916853

Group type: EXPERIMENTAL
Intervention: Professionally supported education
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Private instruction by parents or other private teachers
Number of subjects: 2000
Study: 31347016

Group type: EXPERIMENTAL
Intervention: PATHS curriculum
Number of subjects: 5218

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 5218
Study: 31119469

Group type: EXPERIMENTAL
Intervention: Signs of DSED in early childhood
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Diminished signs of DSED by age 12 years
Number of subjects: 136
Study: 27997725

Group type: EXPERIMENTAL
Intervention: Emollient cream (Dexeryl®) containing glycerol 15%, liquid and soft paraffin 10%, and other ingredients, applied twice daily for 27 ± 2 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vehicle (glycerol monostearate, stearic acid, polydimethylcyclosiloxane, silicone oil, macrogol 600, trolamine, propyl parahydroxybenzoate and purified water)
Number of subjects: 57
Study: 27585792

Group type: EXPERIMENTAL
Intervention: Cann‐CBD (8 mg THC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cann + CBD (8 mg THC + 10 mg CBD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cannabis-dependent group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (non-dependent, drug-using)
Number of subjects: 37
Study: 25158709

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections into the orbicularis oris muscle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle injections into the orbicularis oris muscle
Number of subjects: 60
Study: 22178274

Group type: EXPERIMENTAL
Intervention: Two-needle technique for TMJ arthrocentesis plus hyaluronic acid injections
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single-needle technique for TMJ arthrocentesis plus hyaluronic acid injections
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study: 19728752

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 0
Study: 16635050

Group type: EXPERIMENTAL
Intervention: Active analgesics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15579788

Group type: EXPERIMENTAL
Intervention: Low-dose T3 (25 microg) with paroxetine 30 mg daily
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: High-dose T3 (25 microg twice daily) with paroxetine 30 mg daily
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo with paroxetine 30 mg daily
Number of subjects: 113
Study: 11704586

Group type: EXPERIMENTAL
Intervention: Intravenous IL-5 (2 microg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inhaled IL-5 (15 microg)
Number of subjects: 9
Study: 9193050

Group type: EXPERIMENTAL
Intervention: Level discrimination task with varying levels of randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shape discrimination task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detectability of a level increment in a multitone complex
Number of subjects: 0
Study: 12959313

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg day(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Misoprostol with diclofenac
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg day(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2825462

Group type: EXPERIMENTAL
Intervention: atracurium 0.02 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: atracurium 0.03 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: atracurium 0.04 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: atracurium 0.05 mg/kg
Number of subjects: 60
Study: 29792404

Group type: EXPERIMENTAL
Intervention: XIENCE DES
Number of subjects: 170

Group type: COMPARATOR
Intervention: SYNERGY DES
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Culotte stenting
Number of subjects: 170
Study: 27599223

Group type: EXPERIMENTAL
Intervention: Full U.S.-THRIVE condition (direct and indirect PBS)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Indirect-only U.S.-THRIVE condition
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Direct-only U.S.-THRIVE condition
Number of subjects: 208

Group type: COMPARATOR
Intervention: Education/assessment control
Number of subjects: 208
Study: 23765874

Group type: EXPERIMENTAL
Intervention: Stepped care programme to prevent depression and anxiety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stepped care programme
Number of subjects: 0
Study: 23139427

Group type: EXPERIMENTAL
Intervention: Audiovisually cued training (3 times per week for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 21
Study: 20639294

Group type: COMPARATOR
Intervention: Therapeutic interventions
Number of subjects: 41605
Study: 18447946

Group type: EXPERIMENTAL
Intervention: Active treatment with a proton pump inhibitor
Number of subjects: 439
Study: 15890044

Group type: EXPERIMENTAL
Intervention: LTI-SAGE intervention (maximum of 12 groups over 12 months)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 69
Study: 12810925

Group type: EXPERIMENTAL
Intervention: CARD15/NOD2 mutations in RA patients
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (non-RA)
Number of subjects: 210
Study: 10505445

Group type: EXPERIMENTAL
Intervention: Functional treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reposition and splinting
Number of subjects: 29
Study: 7847434

Group type: EXPERIMENTAL
Intervention: TMP/SMX thrice weekly (3 times per week)
Number of subjects: 107

Group type: COMPARATOR
Intervention: TMP/SMX daily (twice daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Leucovorin with TMP/SMX
Number of subjects: 107

Group type: COMPARATOR
Intervention: Non-leucovorin with TMP/SMX
Number of subjects: 107
Study: 1826822

Group type: EXPERIMENTAL
Intervention: High-dose gestagen treatment
Number of subjects: 156

Group type: COMPARATOR
Intervention: Abrasio alone
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combination of abrasio and high-dose gestagen treatment
Number of subjects: 156
Study: 7010164

Group type: EXPERIMENTAL
Intervention: Routine endoscopy
Number of subjects: 206

Group type: COMPARATOR
Intervention: No routine endoscopy
Number of subjects: 206
Study: 31171928

Group type: EXPERIMENTAL
Intervention: Domperidone treatment for 14 days
Number of subjects: 90
Study: 31016268

Group type: EXPERIMENTAL
Intervention: Socio‐Economic‐Health Deprivation Index (SEHDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belonging to families with 3 or 4 members
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population in the Foggia municipality
Number of subjects: 0
Study: 27458060

Group type: EXPERIMENTAL
Intervention: Aerobic physical activity program (120 min/week for 24 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 40
Study: 24163093

Group type: EXPERIMENTAL
Intervention: Continuous intraarticular infusion of 0.2% ropivacaine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Epidural plus femoral nerve block (FNB)
Number of subjects: 94
Study: 23136289

Group type: EXPERIMENTAL
Intervention: Management by lady health workers (LHWs) using oral antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referred cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community managed cases (excluding cost of antibiotics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referred cases (excluding cost of antibiotics)
Number of subjects: 0
Study: 19800973

Group type: EXPERIMENTAL
Intervention: Concentration-controlled (CC) arm
Number of subjects: 0
Study: 17210513

Group type: EXPERIMENTAL
Intervention: Auriculotherapy using magnetic pellets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Semen Vaccariae (control group)
Number of subjects: 60
Study: 14739797

Group type: EXPERIMENTAL
Intervention: 1 ng/ml remifentanil
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 3 ng/ml remifentanil
Number of subjects: 74

Group type: COMPARATOR
Intervention: No remifentanil infusion (control)
Number of subjects: 74
Study: 11175678

Group type: EXPERIMENTAL
Intervention: Timed 'Up & Go' test (TUG) during 'off' phase of levodopa (after 12 hours withdrawal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Timed 'Up & Go' test (TUG) during 'on' phase of levodopa (1 hour after administration)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Timed 'Up & Go' test (TUG) for comparison subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of TUG scores between 'on' and 'off' phases of levodopa
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of TUG scores between subjects with PD and comparison subjects during 'on' phase
Number of subjects: 24
Study: 9833003

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg ethanol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg ethanol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0 g/kg ethanol (control)
Number of subjects: 10
Study: 7949539

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (FeDs, n = 12)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No iron supplementation (FeDns, n = 12)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal iron status (FeN, n = 27)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Iron-deficient patients (FeD)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Epo production
Number of subjects: 51
Study: 3357722

Group type: EXPERIMENTAL
Intervention: Exercise, diet therapy, and behavior change
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diet therapy and behavior change
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 29703187

Group type: EXPERIMENTAL
Intervention: Communities That Care intervention (CTC)
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Control group (non-intervention communities)
Number of subjects: 3500
Study: 27106362

Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus riluzole (50 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluvoxamine plus placebo
Number of subjects: 50
Study: 24753831

Group type: EXPERIMENTAL
Intervention: Percutaneous Dilatational Tracheostomy (PDT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgically Created Tracheostomy (SCT)
Number of subjects: 60
Study: 22487370

Group type: EXPERIMENTAL
Intervention: Homeopathic medicines (specifics not provided)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (100 consecutive new cases)
Number of subjects: 102
Study: 20543758

Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy with home reinforcement (OBVAT)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Home-based pencil push-ups (HBPP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Office-based placebo therapy with home reinforcement (OBPT)
Number of subjects: 221
Study: 18284711

Group type: EXPERIMENTAL
Intervention: CoQ10 (300 mg per day for 20 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (300 mg per day for 20 days)
Number of subjects: 18
Study: 15218517

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 25 mg triamcinolone acetonide
Number of subjects: 187

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 187
Study: 12220476

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast vs Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urinary LTE4 excretion
Number of subjects: 40
Study: 10574416

Group type: EXPERIMENTAL
Intervention: Benidipine treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9180949

Group type: EXPERIMENTAL
Intervention: IFN-alfa 2b 3 MU t.i.w. during 24 weeks (group I)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IFN-alfa 2b 3 MU t.i.w. during 48 weeks (group II)
Number of subjects: 44
Study: 1767175

Group type: EXPERIMENTAL
Intervention: Troxerutine (4 g/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6123277

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine orally at 2200 hours on the evening before surgery and a further 150 mg 1-2 hours before operation (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine with premedication only (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo at 2200 hours and again with premedication on the day of surgery (Group C)
Number of subjects: 90
Study: 30621772

Group type: EXPERIMENTAL
Intervention: Intensive tobacco-related education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-tobacco-related training
Number of subjects: 0
Study: 28687279

Group type: EXPERIMENTAL
Intervention: Expert feedback
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 46
Study: 26252171

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound‐guided TAP blocks using bupivacaine 0.5% 20 mL on each side
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgical site infiltration with liposomal bupivacaine 266 mg diluted to 60 mL
Number of subjects: 60
Study: 24280881

Group type: EXPERIMENTAL
Intervention: Medical therapy (immunosuppressive medications)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: J-pouch surgery
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Permanent ileostomy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Medical therapy (incompletely effective)
Number of subjects: 293
Study: 21769731

Group type: EXPERIMENTAL
Intervention: 3-minute all-out rowing test (3-min RT)
Number of subjects: 18
Study: 19329822

Group type: EXPERIMENTAL
Intervention: rosuvastatin, 20 mg per day
Number of subjects: 17802

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study: 17822465

Group type: EXPERIMENTAL
Intervention: Tamsulosin OCAS 1.5 mg
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 364

Group type: COMPARATOR
Intervention: Tamsulosin OCAS
Number of subjects: 364

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 364
Study: 14704596

Group type: EXPERIMENTAL
Intervention: More efficacious statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination therapy (niacin, bile acid sequestrant, ezetimibe)
Number of subjects: 0
Study: 12191432

Group type: EXPERIMENTAL
Intervention: HealthQuiz (HQ)
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Donor Health Assessment Questionnaire (DHAQ)
Number of subjects: 1239
Study: 9825271

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine (IA) 400 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8126241

Group type: EXPERIMENTAL
Intervention: Degradable controlled release system containing cetylpyridinium chloride (CPC), 9 mg of CPC applied once daily for 4 weeks.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo solution (identical in formation but without active agent), applied once daily for 4 weeks.
Number of subjects: 44
Study: 3081148

Group type: EXPERIMENTAL
Intervention: Combined test of anterior pituitary function using four hypothalamic releasing factors and arginine vasopressin (100 micrograms each of corticotrophin releasing factor, growth hormone releasing factor, luteinising hormone releasing hormone, and 200 micrograms of thyrotrophin releasing hormone; 10 pressor units of arginine vasopressin intramuscularly)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional combined test using insulin together with thyrotrophin releasing hormone and luteinising hormone releasing hormone
Number of subjects: 24
Study: 26845753

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24856191

Group type: EXPERIMENTAL
Intervention: CPP-ACPF paste (MI Paste Plus, GC America, Alsip, IL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23174792

Group type: EXPERIMENTAL
Intervention: Vitamin D, 50,000 IU per week for two months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 26
Study: 20382432

Group type: EXPERIMENTAL
Intervention: Sexual assault/abuse
Number of subjects: 10424

Group type: EXPERIMENTAL
Intervention: Physical assault/abuse
Number of subjects: 10424

Group type: COMPARATOR
Intervention: Life-threatening trauma
Number of subjects: 10424

Group type: COMPARATOR
Intervention: Emotional abuse/neglect
Number of subjects: 10424

Group type: COMPARATOR
Intervention: Major life stress experiences
Number of subjects: 10424

Group type: EXPERIMENTAL
Intervention: Being a woman
Number of subjects: 10424

Group type: EXPERIMENTAL
Intervention: Being White (versus non-White)
Number of subjects: 10424

Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 10424
Study: 18550097

Group type: COMPARATOR
Intervention: Prostate specific antigen (PSA) testing before first biopsy
Number of subjects: 5688

Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA) testing before second biopsy
Number of subjects: 5688
Study: 18955431

Group type: EXPERIMENTAL
Intervention: Treadmill training (12 sessions of 20 minutes each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Weekly phone call (control group)
Number of subjects: 20
Study: 15539895

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 195
Study: 11264333

Group type: EXPERIMENTAL
Intervention: Medication plus 16 sessions of manualized group psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued medication only (fluoxetine)
Number of subjects: 0